Approved: The Life Cycle of Drug Development
Drug development stands at a transformative threshold in modern medicine. Over the past three decades, biotherapeutics have redefined medical innovation, paving the way for treatments that are not only effective but also accessible. This book provides a comprehensive exploration of the intricate wor...
Uloženo v:
| Korporativní autor: | |
|---|---|
| Další autoři: | , |
| Médium: | Elektronický zdroj E-kniha |
| Jazyk: | angličtina |
| Vydáno: |
Cham :
Springer Nature Switzerland : Imprint: Springer,
2025.
|
| Vydání: | 1st ed. 2025. |
| Témata: | |
| On-line přístup: | https://doi.org/10.1007/978-3-031-81787-8 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-81787-8 | ||
| 003 | DE-He213 | ||
| 005 | 20260810170741.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 250429s2025 sz | o |||| 0|eng d | ||
| 020 | |a 9783031817878 |9 978-3-031-81787-8 | ||
| 024 | 7 | |a 10.1007/978-3-031-81787-8 |2 doi | |
| 050 | 4 | |a RM300-666 | |
| 072 | 7 | |a MMG |2 bicssc | |
| 072 | 7 | |a MED071000 |2 bisacsh | |
| 072 | 7 | |a MKG |2 thema | |
| 082 | 0 | 4 | |a 615 |2 23 |
| 245 | 1 | 0 | |a Approved: The Life Cycle of Drug Development |h [electronic resource] / |c edited by Narendra Chirmule, Vihang Vivek Ghalsasi. |
| 250 | |a 1st ed. 2025. | ||
| 264 | 1 | |a Cham : |b Springer Nature Switzerland : |b Imprint: Springer, |c 2025. | |
| 300 | |a 1 online resource (XXV, 634 p. 126 illus.). |b 123 illus. in color. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Foreword 1 -- Foreword 2 -- Life Cycle of Drug Development -- Vaccines as prophylactics and therapeutics -- Discovery of Biologic Drugs: past, present, and future -- Cellular Therapies: from a theoretical concept to an immuno-augmented reality -- Hope Unlocked: Gene therapies with viral vectors and Gene Editing -- Process development for biologic therapeutics -- Manufacturing of biologic therapeutics -- Pharmacology of protein based therapeutics -- The role of biomarkers in clinical development and its relevance in precision medicines -- Examining the Toxicological Landscape of New Molecular Entities and Biotherapeutics -- Perspective on Clinical Trials: What Researchers need to know -- From Orphan Drugs to Inclusive Research: Bridging Global Gaps in Rare Disease Treatment -- N=1: development pipeline for rare diseases -- What Entrepreneurs Need to Know About Intellectual Property When Building a Strong Patent Portfolio -- The power of Data Analytics: manufacturing Quality & Compliance -- Quality Risk Analysis – the key to failure prevention -- Regulatory Strategy -- Epilogue -- APPENDIX. | |
| 520 | |a Drug development stands at a transformative threshold in modern medicine. Over the past three decades, biotherapeutics have redefined medical innovation, paving the way for treatments that are not only effective but also accessible. This book provides a comprehensive exploration of the intricate world of drug development, shedding light on the essential balance between efficiency, regulatory compliance, and quality to achieve both innovation and affordability. Written by leading experts, this guide delves into the multi-faceted process of drug development, covering critical areas such as pharmacology, biomarkers, toxicology, product development, manufacturing, and clinical trials—all framed within the stringent requirements set by the FDA. Readers will find in-depth discussions on the latest technologies, statistical approaches, and quality assurance measures essential to navigating today’s complex regulatory landscape. With practical case studies, project reports, and curated article reviews, this book offers valuable insights into risk assessment and mitigation at every stage of development. It serves as an indispensable resource for students, educators, and industry professionals, aiming to foster a deeper understanding of the challenges and opportunities in drug development and to inspire the next generation of scientific innovators. | ||
| 532 | 8 | |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 588 | |a Print version record. | ||
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Drug delivery systems. | |
| 650 | 0 | |a Toxicology. | |
| 650 | 1 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Drug Delivery. |
| 650 | 2 | 4 | |a Toxicology. |
| 700 | 1 | |a Chirmule, Narendra. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Ghalsasi, Vihang Vivek. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031817861 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031817885 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031817892 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-81787-8 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 912 | |a ZDB-2-237 | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||
| 950 | |a Focus Bundle Biomedical and Human Health Sciences (SpringerNature-85407) | ||